Oramed Pharmaceuticals (ORMP) Competitors $2.11 -0.04 (-1.86%) Closing price 04:00 PM EasternExtended Trading$2.14 +0.04 (+1.66%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. ORKA, CMPS, AUTL, CYRX, CKPT, SNDL, TRDA, OLMA, ARCT, and HRTXShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Oruka Therapeutics (ORKA), COMPASS Pathways (CMPS), Autolus Therapeutics (AUTL), Cryoport (CYRX), Checkpoint Therapeutics (CKPT), SNDL (SNDL), Entrada Therapeutics (TRDA), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Oruka Therapeutics COMPASS Pathways Autolus Therapeutics Cryoport Checkpoint Therapeutics SNDL Entrada Therapeutics Olema Pharmaceuticals Arcturus Therapeutics Heron Therapeutics Oramed Pharmaceuticals (NASDAQ:ORMP) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends. Does the media favor ORMP or ORKA? In the previous week, Oruka Therapeutics had 14 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 19 mentions for Oruka Therapeutics and 5 mentions for Oramed Pharmaceuticals. Oruka Therapeutics' average media sentiment score of 0.73 beat Oramed Pharmaceuticals' score of -0.75 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Oruka Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ORMP or ORKA? Oruka Therapeutics has a consensus target price of $39.86, indicating a potential upside of 276.72%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the MarketBeat Community favor ORMP or ORKA? Oramed Pharmaceuticals received 301 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 71.85% of users gave Oramed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOramed PharmaceuticalsOutperform Votes31971.85% Underperform Votes12528.15% Oruka TherapeuticsOutperform Votes18100.00% Underperform VotesNo Votes Which has better earnings & valuation, ORMP or ORKA? Oramed Pharmaceuticals has higher revenue and earnings than Oruka Therapeutics. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M64.32$5.53M-$0.44-4.80Oruka TherapeuticsN/AN/A-$5.34M-$4.51-2.35 Do institutionals & insiders believe in ORMP or ORKA? 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 13.7% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 22.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is ORMP or ORKA more profitable? Oramed Pharmaceuticals' return on equity of -7.27% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -7.27% -6.20% Oruka Therapeutics N/A -24.96%-21.22% Which has more volatility and risk, ORMP or ORKA? Oramed Pharmaceuticals has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. SummaryOruka Therapeutics beats Oramed Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.19M$6.49B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio19.188.9326.5819.71Price / Sales64.32251.28391.69116.98Price / CashN/A65.8538.2534.62Price / Book0.526.466.794.50Net Income$5.53M$143.98M$3.23B$248.18M7 Day Performance-4.52%3.02%4.03%1.14%1 Month Performance-6.22%7.45%12.50%15.19%1 Year Performance-8.66%-2.42%16.73%6.55% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.7805 of 5 stars$2.11-1.9%N/A-9.3%$86.19M$1.34M19.1810Earnings ReportORKAOruka Therapeutics2.3909 of 5 stars$9.75+2.2%$39.86+308.8%N/A$365.05MN/A-1.56N/ANews CoverageEarnings ReportAnalyst RevisionCMPSCOMPASS Pathways2.2133 of 5 stars$3.91+3.2%$20.20+416.6%-41.7%$363.04MN/A-1.78120Gap UpAUTLAutolus Therapeutics3.222 of 5 stars$1.35+2.3%$9.32+590.4%-61.9%$359.23M$10.12M-1.12330High Trading VolumeCYRXCryoport3.0174 of 5 stars$7.15+1.1%$11.00+53.8%-43.2%$358.48M$214.83M-2.121,020News CoveragePositive NewsCKPTCheckpoint Therapeutics2.0613 of 5 stars$4.16-0.2%$4.33+4.2%+104.9%$348.46M$41,000.00-2.2610News CoverageNegative NewsSNDLSNDL3.0889 of 5 stars$1.32+2.3%$3.63+174.6%-44.6%$346.86M$927.61M-4.26580News CoveragePositive NewsTRDAEntrada Therapeutics2.9644 of 5 stars$8.82+5.3%$25.67+191.0%-46.2%$334.75M$172.22M5.55110News CoverageAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals2.2698 of 5 stars$4.76+3.5%$27.67+481.2%-46.6%$325.40MN/A-2.1770Positive NewsGap UpARCTArcturus Therapeutics2.9347 of 5 stars$11.59+5.6%$59.20+410.8%-58.4%$314.33M$138.39M-5.22180Gap UpHRTXHeron Therapeutics3.8862 of 5 stars$2.05-2.8%$5.50+168.3%-43.5%$312.76M$148.52M-11.39300Positive News Related Companies and Tools Related Companies Oruka Therapeutics Competitors COMPASS Pathways Competitors Autolus Therapeutics Competitors Cryoport Competitors Checkpoint Therapeutics Competitors SNDL Competitors Entrada Therapeutics Competitors Olema Pharmaceuticals Competitors Arcturus Therapeutics Competitors Heron Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORMP Stock Free ORMP Stock Alerts